Gradalis has promoted Phillip Maples as executive vice president and chief technical officer.
Maples joined the company as its first employee in 2005, and in his new role will continue to oversee product development, manufacturing, and quality assurance.
Before Gradalis, Maples held various roles at Baxter Healthcare, US Oncology, and CellExSys.
Therapeutic protein developer Ablnyx has appointed Catherine Moukheibir it is board of directors.
Moukheibir is currently a board member of Innate Pharma and an independent director of Creabilis. She previously served as vice president of Spanish RNAi drug developer Sylentis.